UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

P0442 : UDCA-LPE modulates different signaling pathways involved in hepatic fibrogenesis

Journal of hepatology, 2015-04, Vol.62, p.S478-S478

2015

Volltextzugriff (PDF)

The Bile Acid-Phospholipid Conjugate Ursodeoxycholyl Lysophosphatidylethanolamide Disturbs Pro-Fibrogenic Integrin and TGFB Signaling

Journal of hepatology, 2016, Vol.64 (2), p.S708-S708

2016

Volltextzugriff (PDF)

Use of the 6 million viral load cut-off to guide treatment duration with ledipasvir/sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection: results from the German Hepatitis C-Registry (DHC-R)

Journal of hepatology, 2017, Vol.66 (1), p.S519-S520

2017

Volltextzugriff (PDF)

Long-term follow-up after IFN-free therapy of advanced HCV-associated liver cirrhosis: continued improvement of liver function parameters – Results from the German Hepatitis C-Registry (DHC-R)

Journal of hepatology, 2017, Vol.66 (1), p.S55-S55

2017

Volltextzugriff (PDF)

Carriers of the ABCB4 PT175A Allele might be At-Risk of Increased Liver Injury: Analysis of Two Independent Cohorts of Patients

Journal of hepatology, 2016, Vol.64 (2), p.S730-S731

2016

Volltextzugriff (PDF)

Ledipasvir/Sofosbuvir Treatment for 8 Weeks in Treatment-Naïve HCV Genotype 1 Infected Patients under Real Life Conditions: Data from the German Hepatitis C-Registry (DHC-R)

Journal of hepatology, 2016, Vol.64 (2), p.S810-S810

2016

Volltextzugriff (PDF)

Point-of-care PT and aPTT in patients with suspected deficiencies of coagulation factors

International journal of laboratory hematology, 2016-08, Vol.38 (4), p.426-434

2016

Volltextzugriff (PDF)

Six Weeks of Sofosbuvir/Ledipasvir (SOF/LDV) are Sufficient to Treat Acute Hepatitis C Virus Genotype 1 Monoinfection: The Hepnet Acute HCV IV Study

Journal of hepatology, 2016, Vol.64 (2), p.S211-S211

2016

Volltextzugriff (PDF)

117 THE BILE ACID PHOSPHOLIPID CONJUGATE URSODEOXYCHOLYL LYSOPHOSPHATIDYLETHANOLAMIDE EXERTS ANTI-FIBROGENIC EFFECTS AND INHIBITS EPITHELIAL-TO-MESENCHYMAL TRANSITION BY BLOCKING TGFβ1/SMAD2/3 SIGNALING

Journal of hepatology, 2011-03, Vol.54, p.S52-S52

2011

Volltextzugriff (PDF)

1281 URSODEOXYCHOLYL LYSOPHOSPHATIDYLETHANOLAMIDE (UDCA-LPE) EVOKES HEPATOPROTECTION VIA G-PROTEIN COUPLED RECEPTORS AND BY MODULATING DESATURASE GENE EXPRESSION

Journal of hepatology, 2011-03, Vol.54, p.S505-S505

2011

Volltextzugriff (PDF)

Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus‐infected patients with renal impairment: results from a 7‐year, multicentre retrospective cohort study

Alimentary Pharmacology & Therapeutics (Suppl), 2020-08, Vol.52 (3), p.500-512

2020

Volltextzugriff (PDF)

132 IMPROVEMENT OF HEPATIC INJURY AND STEATOSIS BY THE BILE ACID-PHOSPHOLIPID CONJUGATE UR- SODEOXYCHOLYL LYSOPHOSPHATIDYLETHANOLAMIDE IN A HIGH-FAT INDUCED DIETARY MODEL OF NONALCOHOLIC FATTY LIVER DISEASE

Journal of hepatology, 2009, Vol.50, p.S54-S54

2009

Volltextzugriff (PDF)

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial

The lancet. Gastroenterology & hepatology, 2019-10, Vol.4 (10), p.781-793

2019

Volltextzugriff (PDF)

Nichtalkoholische Fettlebererkrankung (NAFLD). Epidemiologie, Pathogenese, Diagnostik und Therapie

Verdauungskrankheiten, 2018-05, Vol.36 (5), p.114-120

2018

Volltextzugriff (PDF)

P0934 : Lysophosphatidylcholine (LPC) as central player for hepatic fat accumulation and inflammation: Implication for pathogenesis of NASH

Journal of hepatology, 2015-04, Vol.62, p.S695-S695

2015

Volltextzugriff (PDF)

Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral treatment

Journal of viral hepatitis, 2019-02, Vol.26 (2), p.224-230

2019

Volltextzugriff (PDF)

Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry

Drugs & aging, 2018-09, Vol.35 (9), p.843-857

2018

Volltextzugriff (PDF)

High SVR 12 rates following treatment with direct acting antiviral agents (DAA) in a German multicentre cohort of HCV/HIV-1 coinfected patients on the transplant waiting list with advanced liver cirrhosis

Journal of hepatology, 2017, Vol.66 (1), p.S526-S526

2017

Volltextzugriff (PDF)

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate

Cancer research (Chicago, Ill.), 2005-07, Vol.65 (14), p.6321-6329

2005

Volltextzugriff (PDF)

The INCA trial (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver Cirrhosis and Ascites): study protocol for a randomized controlled trial

Trials, 2015-03, Vol.16 (1), p.83-83, Article 83

2015

Volltextzugriff (PDF)

Add on Interferon-Alpha-2a for the Treatment of HBeAg Negative Hepatitis B Patients Receiving Effective Nucleos(t)ide Therapy: Interim Results of the Prospective Multicentre PADD-On Trial

Journal of hepatology, 2016, Vol.64 (2), p.S221-S221

2016

Volltextzugriff (PDF)

20 DEFICIENCIES OF CALCIUM-INDEPENDENT PHOSPHOLIPASE A2 BETA IN VIVO CAUSES REDUCED SYSTEMIC LIPIDS AND LIPOPROTEINS CONCOMITANT WITH INCREASED HEPATIC APOPTOSIS AND INFLAMMATION

Journal of hepatology, 2012-04, Vol.56, p.S9-S10

2012

Volltextzugriff (PDF)

SAT-407 - The Bile Acid-Phospholipid Conjugate Ursodeoxycholyl Lysophosphatidylethanolamide Disturbs Pro-Fibrogenic Integrin and TGFB Signaling

Journal of hepatology, 2016, Vol.64 (2), p.S708-S708

2016

Volltextzugriff (PDF)

First data concerning the medical supply of patients with non-alcoholic fatty liver disease in Germany - a survey in university hospital centers of hepatology

Zeitschrift fur Gastroenterologie, 2015-06, Vol.53 (6), p.562

2015

Volltextzugriff (PDF)

1 – 25 von 176

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(162)
Mit Volltextzugriff
(120)

Publikationsform

1 weiteren anzeigen...

Weniger anzeigen...

Sprache

Englisch
(143)
Deutsch
(51)
Japanisch
(8)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Zeitschrift / Serie

5 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 30 Tagen
(1)

Menü

Weitere Dienste

Einstellungen

P0442 : UDCA-LPE modulates different signaling pathways involved in hepatic fibrogenesis

The Bile Acid-Phospholipid Conjugate Ursodeoxycholyl Lysophosphatidylethanolamide Disturbs Pro-Fibrogenic Integrin and TGFB Signaling

Use of the 6 million viral load cut-off to guide treatment duration with ledipasvir/sofosbuvir in patients with chronic hepatitis C virus genotype 1 infection: results from the German Hepatitis C-Registry (DHC-R)

Long-term follow-up after IFN-free therapy of advanced HCV-associated liver cirrhosis: continued improvement of liver function parameters – Results from the German Hepatitis C-Registry (DHC-R)

Carriers of the ABCB4 PT175A Allele might be At-Risk of Increased Liver Injury: Analysis of Two Independent Cohorts of Patients

Ledipasvir/Sofosbuvir Treatment for 8 Weeks in Treatment-Naïve HCV Genotype 1 Infected Patients under Real Life Conditions: Data from the German Hepatitis C-Registry (DHC-R)

Point-of-care PT and aPTT in patients with suspected deficiencies of coagulation factors

Six Weeks of Sofosbuvir/Ledipasvir (SOF/LDV) are Sufficient to Treat Acute Hepatitis C Virus Genotype 1 Monoinfection: The Hepnet Acute HCV IV Study

117 THE BILE ACID PHOSPHOLIPID CONJUGATE URSODEOXYCHOLYL LYSOPHOSPHATIDYLETHANOLAMIDE EXERTS ANTI-FIBROGENIC EFFECTS AND INHIBITS EPITHELIAL-TO-MESENCHYMAL TRANSITION BY BLOCKING TGFβ1/SMAD2/3 SIGNALING

1281 URSODEOXYCHOLYL LYSOPHOSPHATIDYLETHANOLAMIDE (UDCA-LPE) EVOKES HEPATOPROTECTION VIA G-PROTEIN COUPLED RECEPTORS AND BY MODULATING DESATURASE GENE EXPRESSION

Treatment with tenofovir disoproxil fumarate or entecavir in chronic hepatitis B virus‐infected patients with renal impairment: results from a 7‐year, multicentre retrospective cohort study

132 IMPROVEMENT OF HEPATIC INJURY AND STEATOSIS BY THE BILE ACID-PHOSPHOLIPID CONJUGATE UR- SODEOXYCHOLYL LYSOPHOSPHATIDYLETHANOLAMIDE IN A HIGH-FAT INDUCED DIETARY MODEL OF NONALCOHOLIC FATTY LIVER DISEASE

Norursodeoxycholic acid versus placebo in the treatment of non-alcoholic fatty liver disease: a double-blind, randomised, placebo-controlled, phase 2 dose-finding trial

Dynamics of liver stiffness by transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral therapy—Results from the German Hepatitis C‐Registry

Nichtalkoholische Fettlebererkrankung (NAFLD). Epidemiologie, Pathogenese, Diagnostik und Therapie

P0934 : Lysophosphatidylcholine (LPC) as central player for hepatic fat accumulation and inflammation: Implication for pathogenesis of NASH

Estimation of liver fibrosis by noncommercial serum markers in comparison with transient elastography in patients with chronic hepatitis C virus infection receiving direct‐acting antiviral treatment

Effectiveness and Safety of Direct-Acting Antiviral Combination Therapies for Treatment of Hepatitis C Virus in Elderly Patients: Results from the German Hepatitis C Registry

High SVR 12 rates following treatment with direct acting antiviral agents (DAA) in a German multicentre cohort of HCV/HIV-1 coinfected patients on the transplant waiting list with advanced liver cirrhosis

Natural killer cell-mediated lysis of hepatoma cells via specific induction of NKG2D ligands by the histone deacetylase inhibitor sodium valproate

The INCA trial (Impact of NOD2 genotype-guided antibiotic prevention on survival in patients with liver Cirrhosis and Ascites): study protocol for a randomized controlled trial

Add on Interferon-Alpha-2a for the Treatment of HBeAg Negative Hepatitis B Patients Receiving Effective Nucleos(t)ide Therapy: Interim Results of the Prospective Multicentre PADD-On Trial

20 DEFICIENCIES OF CALCIUM-INDEPENDENT PHOSPHOLIPASE A2 BETA IN VIVO CAUSES REDUCED SYSTEMIC LIPIDS AND LIPOPROTEINS CONCOMITANT WITH INCREASED HEPATIC APOPTOSIS AND INFLAMMATION

SAT-407 - The Bile Acid-Phospholipid Conjugate Ursodeoxycholyl Lysophosphatidylethanolamide Disturbs Pro-Fibrogenic Integrin and TGFB Signaling

First data concerning the medical supply of patients with non-alcoholic fatty liver disease in Germany - a survey in university hospital centers of hepatology

Suchergebnisse filtern